$2.58 $0.04 (1.6%)

04:00 PM EDT on 09/13/19

Nabriva Therapeutics (NASDAQ:NBRV)

CAPS Rating: 3 out of 5

Current Price $2.58 Mkt Cap $135.7M
Open $2.58 P/E Ratio 0.00
Prev. Close $2.54 Div. (Yield) $0.00 (0.0%)
Daily Range $2.50 - $2.65 Volume 1,243,164
52-Wk Range $1.42 - $3.27 Avg. Daily Vol. 14

Caps

How do you think NASDAQ:NBRV will perform against the market?

Add Stock to CAPS Watchlist

All Players

14 Outperform
1 Underperform
 

All-Star Players

4 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:NBRV Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:NBRV VS S&P 500 (SPY)

NASDAQ:NBRV Summary

Fools bullish on NASDAQ:NBRV are also bullish on:

Fools bearish on NASDAQ:NBRV are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about NBRV.

Recs

0
Member Avatar AndrewGreenBull (92.94) Submitted: 8/19/2019 11:22:35 PM : Outperform Start Price: $2.40 NASDAQ:NBRV Score: +6.16

NBRV is a good bargin under $3

My takes:

· Xenleta: 5million cases in US, 5-7days course of therapy, $205/275 per treatment day—that is a $6 billion dollars potential market.

· 200 million Market cap is way below its fair value (73 million shares with a price of $2.7 , after market price). The company has a robust pipeline besides Xenleta. CONTEPO will be the next one up for FDA approval. It received CRL in may, but the issue that FDA pointed out was minor. Facility inspections and manufacturing deficiencies at one of its contract manufacturers can be fixed. The FDA did not request any new clinical data or raise any safety concerns. It will be resubmitted for NDA early next quarter, and expected next PDUFA in six months after submission.

· NBRV signed a deal with a Chinese company in 2018 to sell in China, where has bigger market than the US.

“Under the terms of the agreement Roivant Sciences of Hong Kong will make an upfront payment of $5 million to Nabriva, which is based in Dublin, Ireland, and has its U.S. headquarters in King of Prussia. Narbiva (NASDAQ: NBRV) would be eligible for additional payments, described as "about $90 million," tied to achieving milestones related to the development of its new drug candidate Lefamulin. If the product is approved in China, Nabriva would also receive royalty payments.”

· The company has about 74 million cash, cash equivalents and short-term investments and existing cash resources are expected to fund operations into the second quarter of 2020 according to its recent quarterly report. That means no public offering in the near term.

Recs

0
Member Avatar TMFTypeoh (92.57) Submitted: 10/23/2017 1:20:22 PM : Outperform Start Price: $6.10 NASDAQ:NBRV Score: -74.89

Next-generation antibiotics play. Approaching this as a basket.

Leaderboard

Find the members with the highest scoring picks in NBRV.

Score Leader

HDTVBG

HDTVBG (33.35) Score: +220.10

Highly dilutive secondary offering just turned all longs into bag holders. Hedge funds to the rescue ???

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
HDTVBG 33.35 9/9/2019 Outperform 3W $2.04 +26.47% +0.66% +25.81 0 Comment
zzlangerhans 99.82 3/18/2019 Underperform 1Y $2.88 -10.42% +6.94% +17.36 0 Comment
AndrewGreenBull 92.94 7/22/2019 Outperform 5Y $2.40 +7.50% +1.34% +6.16 1 Comment
jeepdrew222 55.54 8/28/2018 Outperform 5Y $2.72 -5.15% +3.72% -8.87 0 Comment
karakartal < 20 10/4/2018 Outperform 5Y $3.05 -15.41% +3.40% -18.81 0 Comment
stainsolution < 20 12/20/2017 Outperform 5Y $5.67 -54.50% +12.23% -66.73 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. MarkBiotech < 20 11/6/2017 Outperform 5Y $6.01 -57.07% +16.27% -73.34 0 Comment
efarev 98.09 10/24/2017 Outperform 5Y $6.04 -57.28% +17.34% -74.62 0 Comment
TMFTypeoh 92.57 10/23/2017 Outperform 5Y $6.10 -57.70% +17.19% -74.89 1 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. gunda7907 < 20 10/9/2017 Outperform 5Y $8.15 -68.34% +18.43% -86.78 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NBRV.